BPGbio
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
500 Old Connecticut Path, Framingham, Ma...Phone Number
(617) 588-0083Website
www.bpgbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About BPGbio
BPGbio is a leading AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology, and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBios novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, protected by over 450 US and international patents; the worlds largest clinically annotated non-governmental biobank; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way we understand aging, human performance, and diagnose and treat disease.Explore more
BPGbio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BPGbio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
BPGbio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on BPGbio recently announced quarterly report
Funding: Get notified immidiatlly once BPGbio has new funding data
Check out if BPGbio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if BPGbio had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at BPGbio
Check if BPGbio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when BPGbio launches new products
Recommended Actions
Find VP level buyers at BPGbio
Find more new buyers
Compare Similar Companies to BPGbio
Compare insights from companies similar to BPGbio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BPGbio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BPGbio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BPGbio.
BPGbio Tech Stack
A closer look at the technologies used by BPGbio
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
BPGbio News & Media
BPGbio to Present Ongoing Phase 2 Study Trial-in-Progress Update of BPM31510 in Newly Diagnosed Glioblastoma at ASCO 2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a clinical-stage biopharmaceutical company advancing mitochondrial-targeted therapeutics for patients, today announced that new clinical progress from its ongoing Phase 2 study of BPM31510 in newly diagnosed glioblastoma multiforme (GBM) will be presented at the upcoming ASCO Annual Meeting.BPGbio Appoints Former Oxford Pro-Vice Chancellor for Innovation Chas Bountra, Ph.D., as Executive Vice President and Chief Scientific Officer
• Former Oxford Pro-Vice-Chancellor for Innovation and former Head of Biology at GSK to lead company’s R&D • Longstanding Scientific Advisory Board Chair steps into an expanded leadership role to accelerate the company’s advanced-stage pipeline and translational strategy for the NAi platform.Landmark Living Brain Study Published in CELL Identifies a Novel Molecular Roadmap Governing Human Brain Aging
Mount Sinai and BPGbio scientists uncover novel molecular drivers from live brain samples that direct human brain structure and function from early development through aging:UPDATE - BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency
BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead candidate, BPM31510, for the treatment of primary coenzyme Q10 (CoQ10) deficiency (PCQD).
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BPGbio
Sign Up For FreeTo access detailed company insights
BPGbio is a leading AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology, and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBios novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, prote... Read More
